Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment

Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almost 10 years. Regorafenib resulted in a significant improvemen...

Full description

Saved in:
Bibliographic Details
Main Authors: Bo Hyun Kim (Author), Joong-Won Park (Author)
Format: Book
Published: Korean Liver Cancer Association, 2021-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available